High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma

Bone Marrow Transplantation

Volumn 41, Issue 1, 2008, Pages 51-54

  Maisnar, V ^a   Hajek R ^b   Scudla V ^c   Gregora, E ^d   Buchler T ^b   Tichy M ^a   Kotoucek P ^e   Kafkova A ^f   Forraiova L ^g   Minarik J ^c   Radocha, J ^a   Blaha V ^h   Maly J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^f L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

^g FNsP J A Reimanna   (Slovakia)

^h UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN D; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; MALE; MONOTHERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN D; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 38349023100     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705881     Document Type: Article

References (26)

1. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259-1272.
2. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Internal Med 1975; 135: 87-93.
3. Sinclair D. IgD myeloma: Clinical, biological and laboratory features. Clin Lab 2002; 48: 617-622.
4. Fahey JL, Carbone PP, Rowe DS, Bachmann R. Plasma cell myeloma with D-myeloma protein (IgD myeloma). Am J Med 1968; 45: 373-380.
5. Rowe DS, Fahey JL. A new class of human immunoglobulins. I. A unique myeloma protein. J Exp Med 1965; 121: 171-184.
6. Rowe DS, Fahey JL. A new class of human immunoglobulins. II. Normal serum IgD. J Exp Med 1965; 121: 185-199.
7. Shimamoto Y, Anami Y, Yamaguchi M. A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients. Eur J Haematol 1991; 47: 262-267.
8. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: Presenting features, response to therapy and survival in aseries of 53 cases, J Clin Oncol 1994; 12: 2398-2404.
9. Bemelmans RH, van Toorn DW, van Leeuwen L, Schaar CG. Long-term complete remission in IgD-myeloma. Eur J Haematol 2006; 76: 339-341.
10. Blade J, Kyle RA. IgD monoclonal gammopathy with long-term follow-up. Br J Haematol 1994; 88: 395-396.
11. Kyle RA. IgD multiple myeloma: A cure at 21 years. Am J Hematol 1988; 29: 41-43.
12. Hiyoshi M, Hashimoto S, Ota T, Nakao T, Takubo T, Tagawa S et al. Long-term survival in a case of high-risk type IgD myeloma: A possibility of effectiveness of interferon-alpha and erythropoietin. Haematologia (Budapest) 1997; 28: 177-180.
13. Wechalekar A, Amato D, Chen C, Keith SA, Reece D. IgD multiple myeloma - a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol 2005; 84: 115-117.
14. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment ahd survival. Cancer 1975; 36 842-854.
15. Greipp PR, San Miguer JS, Durie BGM, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
16. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
17. Durie BGM, Harousseau J-L, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467-1473.
18. Spertini F, Tissot JD, Dufour N, Francillon C, Frei PC. Role of two-dimensional electrophoretic analysis in the diagnosis and characterization of IgD monoclonal gammopathy. Allergy 1995; 50 664-670.
19. Kuliszkiewicz-Janus M, Zimny A, Sokolska V, Sasiadek M, Kuliczkowski K. Immunoglobulin D myeloma - problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma 2005; 46: 1029-1037.
20. Tichy M, Budina M, Andrys C, Maisnar V, Vavrova J, Serclova H et al Evalualion of the Czech External Quality Assessment System of monoclonal immunoglobulin in the period of 1996-2005. Klin Biochem Metab 2006; 14: 157-160.
21. Albarede S, Hattchouel JM, Guyard A, Nicolas A, Burg E, Daunizeau A et al. Monoclonal Immunoglobulin: National external quality assessment and diagnostic reasoning (article in French). Ann Biol Clin (Paris) 2005; 63: 107-112.
22. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Inter Groupe Francais du Myeloma (IFM). N Engl J Med 1996; 335: 91-97.
23. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 2001; 38: 21-27.
24. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Lon-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158-164.
25. Hayashi T, Yamaguchi I, Saitoh H, Takagi M, Nonaka Y, Nomura T. Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med 2003; 42: 605-608.
26. Schmielau J, Teschendorf C, Konig M, Schmiegel W, Graeven U. Combination of bortezomib, thalidomide and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma 2005; 46: 567-569.